

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

JENNEWEIN BIOTECHNOLOGIE GmbH
Petitioner

v.

GLYCOSYN LLC
Patent Owner

Case No.: PGR2019-00023
Patent 9,970,018

PETITION FOR POST-GRANT REVIEW
OF U.S. PATENT NO. 9,970,018

TABLE OF CONTENTS

	Page
I. MANDATORY NOTICES PURSUANT TO 37 C.F.R. § 42.8	3
A. Real Parties-In-Interest.....	3
B. Related Matters.....	3
C. Lead and Backup Counsel.....	3
D. Service Information.....	4
E. Payment of Fees	5
II. BACKGROUND OF THE TECHNOLOGY AT ISSUE	5
III. THE '018 PATENT.....	8
A. General Overview of Claimed Subject Matter.....	10
B. The Challenged Claims	12
C. Prosecution History of the '018 Patent's Great-Grandparent: the '230 Patent.....	13
1. The Examiner's First Enablement Rejection.....	13
2. The Examiner's Second Enablement Rejection	15
3. The Examiner's Third Enablement Rejection	17
4. The Examiner's Fourth Enablement Rejection.....	18
5. The Second RCE.....	18
D. Prosecution History of the '018 Patent	19
IV. CLAIM CONSTRUCTION	20
V. STANDING.....	20
A. Eligibility for PGR Turns on Whether a pre-March 16, 2013 Application Satisfies the Written Description and Enablement Requirements for Each Claim of the Challenged Patent.....	22
B. The Earlier-Filed Applications Fail to Enable the Full Scope of at Least Claim 1 of the '018 Patent.	25
1. Enablement Case Law.....	26

TABLE OF CONTENTS

(continued)

	Page
2. Failure of the '230/'018 Patent Specification to Enable the Range of "0.05 and 200 Units" Recited by Claim 1 of the '018 Patent	27
VI. ARGUMENTS FOR UNPATENTABILITY	37
A. Ground 1: Claims 1-28 Are Indefinite for Failing to Specify Precisely How to Measure β -Galactosidase Activity.....	39
1. Different Miller Methods Lead to Different Miller Units.	41
2. Imprecise Amounts of Permeabilizing Solvent in the Miller Assay Lead to Varied Miller Units.	44
3. Miller Units Results Depend on Unspecified Assay Conditions such as Length of Incubation Period, Culture Volume and Stage, and Others.....	46
4. The Patent Fails to Teach When to Measure β -Galactosidase Activity.	51
B. Ground 2: Claim 1-28 Are Indefinite For Reciting That the Activity Level "Comprises" a Range.....	53
C. Ground 3: Claims 1-17 and 19-24 Are Not Enabled by the '018 Patent's Specification.....	56
VII. CONCLUSION.....	57

PETITIONER'S EXHIBIT LIST

Exhibit #	Description
1001	U.S. Patent 9,970,018 (the "'018 patent")
1002	Prosecution History of the '018 Patent
1003	U.S. Patent No. 9,453,230 (the "'230 patent")
1004	Prosecution History of the '230 Patent
1005	U.S. Patent No. 9,587,241
1006	U.S. Patent Application No. 15/442,131
1007	U.S. Provisional Patent Application No. 61/443,470
1008	April 7, 2016 Declaration of Co-Inventor John McCoy (the "Second McCoy Declaration")
1009	Miller, J.H., <i>Experiments in Molecular Genetics</i> (Cold Spring Harbor Lab. 1972), pp. 352-55 ("Miller")
1010	Giacomini, et al., "Experimental conditions may affect reproducibility of the β -galactosidase assay," <i>FEMS Microbiology Letters</i> , 100 (1992), pp. 87-90
1011	Glycosyn LLC GRAS Notice, GRN 735
1012	Goehring et al., Similar to Those who are Breastfed, Infants Fed a Formula Containing 2'- Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial, <i>J. Nutr.</i> 146 (12) 2559-2566 (2016)
1013	Marriage et al., Infants Fed a Lower Calorie Formula With 2'-FL Show Growth and 2'-FL Uptake Like Breast-Fed Infants, <i>JPGN</i> 61: 649-658 (Marriage et al. (2015)

Patent No. 9,970,018
Petition for Post-Grant Review
PGR2019-00023

Exhibit #	Description
1014	Puccio et al., Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial, JPGN 64 (4) 624- 631 (2017)
1015	<i>Curriculum Vitae</i> of Dr. Stephanopoulos
1016	Halford, Bethany, “How is directed evolution changing the world? Newly minted Nobelist Frances Arnold talks about the past and future of evolved enzymes,” Chemical & Engineering News, Vol. 96, Iss. 44, Oct. 30, 2018.
1017	Declaration of Dr. Stephanopoulos

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.